多囊卵巢综合征胰岛素抵抗相关治疗进展  

Progress in treatment of insulin resistance in polycystic ovary syndrome

作　　者：徐洪丽[1] 伍学焱[1] 

机构地区：[1]中国医学科学院北京协和医学院北京协和医院内分泌科卫生部内分泌重点实验室,北京100730

出　　处：《基础医学与临床》2013年第2期231-234,共4页Basic and Clinical Medicine

基　　金：国家自然科学基金(81100416)

摘　　要：胰岛素抵抗(IR)是多囊卵巢综合征(PCOS)重要发病机制之一。临床上应用二甲双胍或噻唑烷二酮类药物可改善PCOS患者IR,纠正其代谢紊乱和高雄激素血症,故有助于恢复正常月经,增加排卵率及妊娠率,且孕期应用二甲双胍可能减少流产、妊娠高血压病、妊娠糖尿病等并发症。Insulin resistance plays a key role in the pathogenesis of polycystic ovary syndrome. Therefore thiazo- lidinediones and metformin which have been used in clinical therapy to treat patients with polycystic ovary syndrome can ameliorate insulin resistance, resulting in the improvement of some metabolic abnormalities, hyperandrogenic symptoms, menses, ovulation and pregnancy rates. Metformin therapy throughout pregnancy may reduce in preg- nancy complications, such as miscarriage rate, gestational hypertension and gestational diabetes.

关 键 词：多囊卵巢综合征 胰岛素抵抗 二甲双胍 噻唑烷二酮类药物 

分 类 号：R711.75[医药卫生—妇产科学]